Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
← catalyst calendarNCT05519449 · readout ≤ 346 d
Sponsored by Janux Therapeutics (industry) · JANX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
272estimated
Sites
36
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-15 | actual | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Castration Resistant Prostatic Cancer
Interventions
- Biological: JANX007
- Drug: Darolutamide
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLT)
measured 3 years
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
measured 3 years
Permalink · JANX's whole pipeline · Catalyst calendar · Every registered study · What changed